Renhong Tang, Simcere co-CEO

Almi­rall part­ners up with Sim­cere in po­ten­tial $500M+ deal — with plans to take IL-2 can­di­date glob­al

A Chi­nese phar­ma is look­ing to go in­ter­na­tion­al with one of its pre­clin­i­cal can­di­dates, and it’s team­ing up with a Span­ish com­pa­ny in a new pact po­ten­tial­ly worth half a bil­lion dol­lars to do just that.

Sim­cere and Almi­rall an­nounced Thurs­day that the two com­pa­nies had reached a deal for Sim­cere’s IL-2 mu­tant fu­sion pro­tein drug can­di­date, called SIM0278. Ac­cord­ing to a state­ment, Almi­rall gets an ex­clu­sive right to de­vel­op and com­mer­cial­ize the drug can­di­date in all in­di­ca­tions and mar­kets out­side of Chi­na, Hong Kong, Tai­wan and Macau.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.